Age-related macular degeneration (AMD) is one of the leading causes of vision loss among adults over 65. This condition ...
The research team is now monitoring 12 more participants who received higher doses of 150,000 and 250,000 cells. If no safety ...
A first-of-its-kind trial is testing adult stem cell transplants for advanced dry macular degeneration. Early results show ...
EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics ...
The overall dry AMD market size in the US is anticipated to increase, due to the uptake of recently approved therapies, the launch of emerging therapies such as Gildeuretinol (Alkeus Pharmaceuticals), ...
First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...
The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...
Coave Therapeutics has announced its lead gene therapy program, CoTx-101, for the treatment of retinal vascular diseases, ...
In a first-in-human phase 1/2a clinical trial, researchers used adult stem cells to help restore vision in people with age-related macular degeneration. In the United States, age-related macular degen ...
A new approach pioneered by Aalto University scientists uses controlled warmth to trigger self-repair within retinal cells ...
ANNX advances tanruprubart for Guillain-Barré syndrome, with an EMA filing planned for January 2026 and ongoing FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback